At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 152 enrolled
Drug / intervention
Panitumumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating Panitumumab and Cisplatin for Cancer and 3 related conditions. Completed, enrolled 152 participants.
Detailed Summary
The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first line treatment for locally advanced squamous cell carcinoma for the head and neck (SCCHN). A formal hypothesis will not be tested in this trial; however, the treatment arm difference in LRC rates at 2 years will be estimated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Head and Neck Cancer, Oncology, Squamous Cell Carcinoma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartNov 2007
Primary CompletionDec 2011
Study CompletionMar 2012
TodayJul 2026
First PostedOct 22, 2007
Enrollment StartNov 1, 2007
Primary CompletionDec 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 18.7 years ago
Interventions
Panitumumabdrug
Arm 2 consists of panitmumab plus RT
Cisplatindrug
Cisplatin